Answers are grounded in this paper and cite their sources.
Controlled animal study demonstrates reduced blood glucose and improved lipid profiles in diabetic rats, highlighting the therapeutic potential of tartary buckwheat bioactive extracts.
This study was conducted to assess the anti-hyperlipidemic and anti-hyperglycemic effects of buckwheat extract on diabetic Albino rats. In addition, we have also assessed the concentration of bioactive compounds in milling fractions and protein quality of buckwheat. The results indicated that the tartary buckwheat contained a higher quantity of bioactive compounds compared to common buckwheat. Significantly higher rutin (32.98 mg/100g), D-chiro-inositol (DCI) (141.93 mg/100g), and quercetin (1.64 mg/100g) was observed in husk part of tartary buckwheat while lowest rutin (10.94 mg/100g), DCI (14.66 mg/100g), and quercetin (0.52 mg/100g) was found in fine flour of tartary buckwheat. The results revealed that the nutritional and biological value of rats fed on buckwheat containing diet improved significantly. The buckwheat extract significantly reduced the total cholesterol, triglycerides and low-density lipoproteins, whereas these levels increased in control groups. In the case of high-density lipoproteins (HDL), a decreasing trend was observed in the control group, while an increasing trend was observed in the groups that received buckwheat extract. The buckwheat extract effectively decreased the glucose level, and the highest decrease was found in T4 (diabetic rats given the 180 mg/kg tartary buckwheat extract) after 21 days study, while glucose level increased in control groups. The findings from this study revealed that the buckwheat extract contains an effective amount of DCI, rutin, and quercetin that play a very important role in the reduction of cholesterol and blood glucose level.
No takes yet. Share an insight, caveat, or question.
Mazahir et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: